KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $2.0 million.

  • AbCellera Biologics' Amortizatization of Intangibles fell 93.99% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 78.58%. This contributed to the annual value of $78.3 million for FY2024, which is 572.96% up from last year.
  • AbCellera Biologics' Amortizatization of Intangibles amounted to $2.0 million in Q3 2025, which was up 25.24% from $1.6 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Amortizatization of Intangibles high stood at $33.1 million for Q3 2024, and its period low was $1.3 million during Q1 2025.
  • In the last 3 years, AbCellera Biologics' Amortizatization of Intangibles had a median value of $2.7 million in 2023 and averaged $8.6 million.
  • In the last 5 years, AbCellera Biologics' Amortizatization of Intangibles soared by 2,340.59% in 2021 and then tumbled by 95.16% in 2025.
  • Over the past 5 years, AbCellera Biologics' Amortizatization of Intangibles (Quarterly) stood at $2.6 million in 2021, then soared by 320.00% to $11.0 million in 2022, then slumped by 66.94% to $3.7 million in 2023, then soared by 186.53% to $10.5 million in 2024, then crashed by 93.99% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles was $2.0 million in Q3 2025, compared to $1.6 million in Q2 2025 and $1.3 million in Q1 2025.